Abnormal Cannabidiols for Glaucoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, which involve ocular hypotensive agents, often cause ocular surface hyperemia and are not as effective in lowering intraocular pressure as desired, particularly in chronic open-angle glaucoma where aqueous humor outflow is obstructed.
Innovation Solution
The use of Abnormal Cannabidiols and their homologues and derivatives, represented by specific chemical formulas, which are administered topically as ophthalmic solutions to reduce intraocular pressure without causing significant ocular surface hyperemia, are effective in treating glaucoma by acting as potent ocular hypotensive agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stress or pressure
If traditional ocular hypotensive agents are used to treat glaucoma, then intraocular pressure is lowered, but ocular surface hyperemia occurs
Solution Approach 1:
The patent changes the chemical parameters of the ocular hypotensive agent by using abnormal cannabidiols with specific molecular structures (formula I) that have different pharmacological properties compared to traditional agents. This chemical parameter change allows achieving intraocular pressure reduction without the harmful ocular surface hyperemia effect, as demonstrated in the animal model data showing IOP reduction with minimal hyperemia compared to traditional agents like PGF2α and latanoprost
2Stress or pressure
If conventional glaucoma medications are administered, then aqueous humor outflow obstruction is addressed, but effectiveness in lowering intraocular pressure is insufficient
Solution Approach 1:
The patent creates novel chemical compounds (abnormal cannabidiols) that are structural analogs or derivatives of natural cannabinoids, modifying their molecular structure (formula I with specific R groups and Q moieties) to enhance their pharmacological activity. This molecular copying and modification results in compounds with superior intraocular pressure reduction effectiveness compared to conventional glaucoma medications, as shown in the patent's experimental data
Data Source
AI summary
The present invention provides a method of treating glaucoma or ocular hypertension which comprises applying to the eye of a person in need thereof an amount sufficient to treat glaucoma or ocular hypertension of a compound of formula Iwherein Y, Q, Z, R, R1 and R2 are as defined in the specification.The present invention further comprises pharmaceutical compositions, e.g. ophthalmic compositions, including said compound of formula I.